Detalhe da pesquisa
1.
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
J Am Acad Dermatol
; 84(5): 1269-1277, 2021 May.
Artigo
Inglês
| MEDLINE | ID: mdl-32950546
2.
Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).
J Drugs Dermatol
; 20(4): 436-441, 2021 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33852252
3.
Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.
J Dermatolog Treat
; 33(4): 2297-2304, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-34365872
4.
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics.
Dermatol Ther (Heidelb)
; 11(5): 1657-1665, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-34339017